Gut Microbiota Composition for DNase Modulation and Barrier Integrity

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current compositions fail to effectively modulate deoxyribonuclease activity, leading to issues such as intestinal barrier dysfunction, neurodegenerative diseases, and various chronic conditions like diabetes and cancer, due to the formation of bacterial amyloid and DNA-protein complexes in the gut microbiota.

Innovation Solution

Compositions comprising magnesium and sodium cations, along with additives like ascorbic acid and plant extracts, are used to modulate DNase activity, preventing DNA-protein complex formation and maintaining gut barrier function.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current compositions are used, then DNase activity modulation is insufficient, but intestinal barrier dysfunction and disease risk increase

Engineering Contradiction:
ImproveDNase activity modulation effectivenessVSAvoidintestinal barrier dysfunction and disease risk
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical parameters of the composition by specifying precise concentrations of magnesium cations (6.0-155.0 mg/l) and sodium cations (0.005-12.0 mg/l), along with controlled pH levels (6.0-7.5), to optimize DNase activity modulation and prevent pathological conditions

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite water composition containing multiple components working synergistically: magnesium cations, sodium cations, and water, with optional additives like ascorbic acid and plant extracts, to achieve enhanced DNase modulation and gut barrier protection

Inventive Principle:
Principle #40Composite materials

2Stability of the object's composition

If bacterial amyloid and DNA-protein complexes form in the gut, then microbiota stability is maintained, but neurodegenerative and oncological diseases develop

Engineering Contradiction:
Improvemicrobiota stabilityVSAvoidneurodegenerative and oncological diseases
Core Design Contradiction:
Stability of the object's compositionVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful effect of DNA-protein complex formation into a beneficial outcome by using optimized water compositions to modulate DNase activity, which prevents pathological aggregation while maintaining normal microbiota functions, thereby preventing neurodegenerative and cancerous conditions

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

3Object-affected harmful factors

If DNase activity is not properly modulated, then bacterial penetration increases, but current compositions cannot prevent this

Engineering Contradiction:
Improvebacterial penetrationVSAvoidcurrent composition effectiveness
Core Design Contradiction:
Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent optimizes physical-chemical parameters including magnesium concentration (6.0-155.0 mg/l), sodium concentration (0.005-12.0 mg/l), and pH (6.0-7.5) to enhance DNase activity, which in turn reduces bacterial penetration and maintains gut barrier integrity

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compositions enhance DNase activity, reducing bacterial penetration, inhibiting neurodegenerative and oncological diseases, and improving metabolic health by enhancing gut barrier integrity.

Implementation Method 1

Compositions comprising magnesium and sodium cations, along with additives like ascorbic acid and plant extracts, are used to modulate DNase activity

Methodology Applied
Scientific EffectCation-enzyme interaction: Enzyme

Data Source

PatentUS20260078427A1Compositions for modulating gut microbiota
Publication Date: 2026.03.19 TETS

AI summary

The present invention provides compositions that modulate gut microbiota and/or the activity of deoxyribonucleases (e.g., in the gastrointestinal tract) and are useful in the treatment of diseases and disorders related to the activity of deoxyribonucleases including, for example, neurodegenerative, inflammatory, and metabolic diseases and cancer.